NSE
Cura Technologies LimitedCURAA
Cura Technologies Limited is a leading manufacturer of pharmaceuticals, vaccines, and diagnostic products in India. The company develops innovative solutions for various health needs.
| Key products | Pharmaceuticals, Vaccines, Diagnostic Products |
|---|---|
| Geography | India, Middle East, Africa |
| Competitors | Sun Pharma, Dr. Reddy's Laboratories, Cipla Limited |
AI-generated overview — verify before relying on it.
Net institutional flow
−₹0.1 Cr
Institutional buyers
0 in / 1 out
High-impact filings
0 · tilt Neutral
Next corporate action
—
| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | MTNL | +₹41.3 Cr | 331 | — | — | — | — |
| 2 | ATALREAL | +₹7 Cr | 367 | — | — | — | — |
| 3 | GATECH | +₹0.4 Cr | 298 | — | — | — | — |
| 4 | CURAAThis | −₹0.1 Cr | 1 | — | — | — | — |
| 5 | IRMENERGY | −₹2.2 Cr | 356 | — | — | — | — |
| 6 | QUADFUTURE | −₹9 Cr | 581 | — | — | — | — |
| 7 | MOBIKWIK | −₹150.9 Cr | 975 | — | — | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
- 2025-07-15BulkSELL · ₹0.1 CrMULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED
- 2025-07-15NetDay net −₹0.1 Cr
Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.
Filings that matter
No scored filings for CURAA yet.
1 deals · 2025-07-15 → 2025-07-15
| Date | Counterparty | Type | Side | Value |
|---|---|---|---|---|
| 2025-07-15 | MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED | Institution | SELL | ₹0.1 Cr |
1 deal in the selected window — corporate actions are scoped to the same period. ~2 years of history available.
News & chatter on CURAA
RSS News
0No recent news.
Google News RSS — links open the source.
Investdesk
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.